Commercial Kit for screening for hereditary tyrosinemia type 1 (HT1)
Estimated value
£1.7m
Awarded value
£1.7m
Awarded 30 Mar 2025
Suppliers
1
Lots
1
1 awarded
Published
27 Aug 2025
Deadline 31 Mar 2025
Description
Newborn Blood Spot screening (NBS) is a national programme offered to all babies born in the UK, and it currently screens for 9 rare but potentially lethal conditions. The blood spot screening sample is taken from the baby's heel collected on a filter paper dried blood spot (DBS) card. The blood sample is analysed by one of 13 newborn screening laboratories in England
Scope
- Reference
- CF-3150800D0O000000rwimUAA
- Total value
- £1,677,290 excluding VAT
- Commercial tool
- Standalone contract
- Contract dates
- 31 Mar 2025 to 30 Mar 2027
- CPV classifications
- 33696200
Submission & procedure
- Submission deadline
- 31 Mar 2025, 11:00 am
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
£1.7m
Award date
30 Mar 2025
Contract start
31 Mar 2025
Contract end
30 Mar 2027
Awarded to